NTLA vs NOAH Comparison

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Noah Holdings Ltd is a wealth management service provider. It focuses on wealth investment and asset allocation services for high-net-worth individuals and enterprises in China. The company operates through three segments: wealth management, asset management, and other business. Its product offerings consisting of over-the-counter wealth management and OTC asset management products and mutual fund products. The portfolio of the group mostly includes fixed income products, private equity funds and securities investment funds. Majority of the firm revenue is generated through one-time commissions and recurring service fees paid by third-party product providers.